Nov 2008 - ImmuneRegen's product Homspera has shown preclinical effectiveness in protection from radiation exposure, acceleration of wound healing, vaccine adjuvancy, and treatment of infectious diseases, such as influenza and anthrax.

Underlying these results is the ability of Homspera to stimulate stem cells that regenerate and maintain the immune system. For example, the survival increases observed in the Company's radiation studies suggests Homspera mitigates the resulting neutropenia and thrombocytopenia, thereby restoring the damaged immune system.

Homspera is an adult stem cell active compound that, in study results, has been shown that it may have effects on the regeneration and strengthening of the immune system and on enhancing wound healing. To advance its mission, ImmuneRegen BioSciences has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems, Inc.

The company is moving aggressively toward the clinical and human studies in wound healing and blood cell depletion, and they expect to be on target with IND submissions on or before June 2009.